|
| August 21, 2019 |
New ESMO Guidelines on (Neo) Adjuvant Therapy for Early
Breast Cancer
The European Society for Medical Oncology published its clinical practice guidelines on the diagnosis, treatment, and follow-up of early breast cancer. The guidelines cover breast-cancer screening, diagnosis and pathology-molecular biology, staging and risk assessment, treatment (surgical, radiotherapy, and [neo]adjuvant systemic), personalized medicine and follow-up, long-term implications, and survivorship. Read more. |
|
|
Genome-Wide Association Study of Anastrozole Therapy
Anastrozole, an aromatase inhibitor that reversibly and competitively inhibits the enzyme that catalyzes the biosynthesis of estrogens from androgens, is first-line therapy in the management of postmenopausal estrogen-receptor positive breast cancer. However, approximately 10% of patients do not experience a decrease in their estrogen levels and may actually have an increase. Read more. |
|
Updated Nomogram Assesses Recurrence Risk
The use of Oncotype-DX, a reverse-transcriptase–polymerase chain reaction 21-gene assay used by women with hormone receptor positive, HER2 negative, lymph node negative early breast cancer (BC) to predict risk of BC recurrence, is recommended by the National Comprehensive Cancer Network and the American Society of Clinical Oncology, and for staging by the American Joint Commission on Cancer. Read more. | | | Connect With U.S. Pharmacist
    |
|
|
|
|
